MicroVention, a subsidiary of Japanese medical technology firm Terumo, has commercially launched the LVIS EVO Intraluminal Support Device in the US to treat wide neck intracranial aneurysms.

LVIS EVO is said to be the first fully visible coil-assist-intracranial stent available in the American market. The stent has been available in Europe since 2019 with more than 12,000 units sold.

It is intended for use with neurovascular embolisation coils in patients aged 18 and older, specifically for treating wide-neck saccular intracranial aneurysms. These aneurysms must have originated from a parent vessel with a diameter ranging from 2.0mm to 4.5mm.

MicroVention has designed the LVIS EVO with DFT wire construction and an advanced braid design that ensures enhanced visualisation, optimised opening, and precise placement.

According to the neurovascular company, the stent’s entire body is fully visible under fluoroscopy, and the optimised braid angle enables improved device opening across its entire length.

The stent enables controlled delivery and deployment, with the capability to resheath up to 80% of the device length.

Additionally, the entire LVIS EVO product line is compatible with MicroVention’s Headway 17 Advanced Microcatheter as well as the Scepter C and Scepter XC Occlusion Balloons.

MicroVention president and CEO Carsten Schroeder said: “Today’s announcement underscores MicroVention’s commitment to delivering groundbreaking solutions for hemorrhagic stroke treatment.

“MicroVention continues to lead the way in both hemorrhagic and ischemic stroke care. This achievement is a testament to our collaboration with leading physicians worldwide.

“By identifying the evolving needs in patient care and transforming those insights into innovative technologies, we are able to save lives and improve outcomes.”

Based in California, MicroVention develops and commercialises medical devices to improve the treatment of cerebrovascular diseases. Terumo acquired the company in 2006.

Last month, Terumo’s subsidiary Terumo Cardiovascular secured the US Food and Drug Administration (FDA) 510(k) approval for its CDI OneView Monitoring System.